DeepMed Research

PIERRE FABRE MEDICAMENT

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment Patterns of Neratinib in HER2+ EBC in China

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Neratinib

First Posted Date: 2022-08-08

Last Posted Date: 2022-08-08

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 500

Registration Number: NCT05491057

Locations: 🇨🇳
Medical Affair, Shanghai, China

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Encorafenib and Binimetinib
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib

First Posted Date: 2022-03-08

Last Posted Date: 2023-11-22

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 815

Registration Number: NCT05270044

Locations: 🇨🇦
Toronto Sunnybrook Hospital, Toronto, Ontario, Canada
🇦🇹
Krankenhaus der Elisabethinen Linz, Linz, Austria
🇭🇺
Debreceni Egyetem, Debrecen, Hungary

and more 152 locations

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Encorafenib
Drug: Binimetinib

First Posted Date: 2022-01-19

Last Posted Date: 2024-11-13

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 63

Registration Number: NCT05195632

Locations: 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳
Sichuan Cancer Hospital, Chengdu, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 31 locations

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1

Conditions: BRAF V600 Mutation
Melanoma
Unresectable Melanoma
Metastatic Melanoma

Interventions: Drug: Binimetinib Oral Tablet

First Posted Date: 2021-11-02

Last Posted Date: 2021-12-01

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 14

Registration Number: NCT05103891

Locations: 🇫🇷
Biotrial, Rennes, France

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer
BRAF V600E

Interventions: Drug: Encorafenib
Drug: Cetuximab
Drug: FOLFIRI

First Posted Date: 2021-08-13

Last Posted Date: 2025-04-15

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 107

Registration Number: NCT05004350

Locations: 🇨🇳
Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China

and more 31 locations

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Phase 1

Completed

Conditions: BRAF V600E Unresectable or Metastatic Melanoma
Melanoma
BRAF V600E Metastatic NSCLC

Interventions: Drug: Encorafenib

First Posted Date: 2021-08-12

Last Posted Date: 2024-06-24

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 3

Registration Number: NCT05003622

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult
Non-small Cell Lung Cancer
Melanoma

Interventions: Drug: KIN-2787 and binimetinib
Drug: KIN-2787

First Posted Date: 2021-06-04

Last Posted Date: 2025-03-19

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 400

Registration Number: NCT04913285

Locations: 🇫🇷
APHM-CHU La Timone, Marseille, France
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 26 locations

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Recruiting

Conditions: Metastatic Melanoma
Melanoma (Skin)
BRAF V600 Mutation

First Posted Date: 2021-06-03

Last Posted Date: 2022-06-02

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 400

Registration Number: NCT04911998

Locations: 🇵🇹
Hospital Evora, Evora, Portugal

Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial

Phase 4

Completed

Conditions: Actinic Keratoses

Interventions: Drug: 5-fluorouracil 4% (Tolak)
Device: Dexeryl

First Posted Date: 2021-05-06

Last Posted Date: 2022-09-19

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 146

Registration Number: NCT04875026

Locations: 🇩🇪
Kath. Klinikum Bochum St. Josef-Hospital, Bochum, Germany
🇩🇪
MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany
🇫🇷
CHU St Etienne Hopital Nord, Saint-Étienne, France

and more 24 locations

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Phase 1

Withdrawn

Conditions: Unresectable Melanoma
Hepatic Impairment
BRAF V600 Mutation
Metastatic Melanoma

Interventions: Drug: Encorafenib + Binimetinib

First Posted Date: 2021-02-18

Last Posted Date: 2023-02-21

Lead Sponsor: Pierre Fabre Medicament

Registration Number: NCT04759846

Locations: 🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Czechia
🇨🇿
Fakultni Nemocnice Kralovske Vinohrady, Praha, Czechia
🇪🇸
all D'Hebron Insitute of Oncology, Barcelona, Spain

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy